MK-2866 and MK-677 Interaction

Synergistic
Researched 95% confidence

MK-2866 and MK-677 have a synergistic interaction with 95% confidence. MK-677 (Ibutamoren) stimulates growth hormone secretion through ghrelin receptor agonism, while MK-2866 provides direct androgen receptor activation in muscle. The combination supports lean mass accrual through complementary mechanisms without additive HPTA suppression, as MK-677 does not affect the androgen axis. Commonly stacked for body recomposition and lean gain goals. These compounds primarily affect different organ systems.

Compound Profiles

MK-2866

Selective Androgen Receptor Modulator | Muscle Wasting Research

MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.

Half-life: ~24 hours Typical dose: 10-25 mg/day oral sarm, anabolic
androgen receptormtormyostatin androgeniccarcinogenic riskhepatotoxichpta suppressive
View full profile

MK-677

Ghrelin Receptor Agonist | Oral Growth Hormone Secretagogue

Selectively binds GHS-R1a receptors in hypothalamus and pituitary, triggering pulsatile growth hormone release while maintaining natural circadian patterns..

Half-life: ~24 hours Typical dose: Start 12.5mg daily, increase to 25mg based on tolerance growth hormone, weight loss, sleep
ghrelin receptor blood pressure raisingcarcinogenic riskhepatotoxicinsulin disrupting
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
Brain
low
GI Tract
low
Pituitary
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (MK-2866, MK-677). Monitor accordingly.
2x 2 hepatotoxic compounds (MK-2866, MK-677). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.

Frequently Asked Questions

Can I take MK-2866 with MK-677?

Yes, MK-2866 and MK-677 can generally be taken together. MK-677 (Ibutamoren) stimulates growth hormone secretion through ghrelin receptor agonism, while MK-2866 provides direct androgen receptor activation in muscle. The combination supports lean mass accrual through complementary mechanisms without additive HPTA suppression, as MK-677 does not affect the androgen axis. Commonly stacked for body recomposition and lean gain goals.

Is MK-2866 and MK-677 safe together?

Based on documented research, this combination is considered synergistic. However, shared safety flags include: carcinogenic risk, hepatotoxic. Monitor accordingly.

What are the interactions between MK-2866 and MK-677?

MK-677 (Ibutamoren) stimulates growth hormone secretion through ghrelin receptor agonism, while MK-2866 provides direct androgen receptor activation in muscle. The combination supports lean mass accrual through complementary mechanisms without additive HPTA suppression, as MK-677 does not affect the androgen axis. Commonly stacked for body recomposition and lean gain goals. This assessment has 95% confidence and is based on documented research data.

How should I time MK-2866 and MK-677?

MK-2866 has a half-life of ~24 hours and MK-677 has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: MK-2866 vs MK-677

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.